By completing the integration of ICON Late Phase, Oxford Outcomes, and PriceSpective, our commitment to providing the very best in product research, development, and commercialisation strategy is stronger than ever. We offer a broader and more coordinated range of expertise and services, all delivered with the same level of excellence and commitment to clients service that you have always known.
The combined strengths in our scientific practices and operational delivery teams offer tremendous opportunity to harness expertise and capabilities from multiple practices at once, or in sequence, creating a stronger and more persistent focus on product value and commercial success than the constituencies alone.
ICON has cemented its position as one of the most highly regarded, widely recognised, broadly geographically represented, and most comprehensive CROs in the world today to support pharmaceutical and biomedical clients taking powerful products to market.
To reflect the evolution of our offerings, we are changing the name of ICON Late Phase & Outcomes Research and its legacy sub-brands, Oxford Outcomes and PriceSpective to ICON Commercialisation & Outcomes.
We have changed our name, but our commitment to providing the very best in product research, development, and commercialisation strategy is stronger than ever.
ICON’s Commercialisation & Outcomes practices provide insight to clients on strategies and execution for long-term value through customised engagements that fit the compound, the company and the market, maximising products' success and their benefits to patients’ health.